A retrospective clinical study of the treatment of slow-channel congenital myasthenic syndrome

Journal of Neurology

Volumn 259, Issue 3, 2012, Pages 474-481

  Chaouch, Amina ^a   Müller, Juliane S ^a   Guergueltcheva, Velina ^b,c   Dusl, Marina ^b   Schara, Ulrike ^d   Rakocević Stojanović, Vidosava ^e   Lindberg, Christopher ^f   Scola, Rosana H ^g   Werneck, Lineu C ^g   Colomer, Jaume ^h   Nascimento, Andres ^h   Vilchez, Juan J ⁱ   Muelas, Nuria ⁱ   Argov, Zohar ^j   Abicht, Angela ^b   Lochmüller, Hanns ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^d UNIVERSITY OF DUISBURG ESSEN   (Germany)

^e UNIVERSITY OF BELGRADE   (Serbia)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^h HOSPITAL SANT JOAN DE DÉU   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

more..

Author keywords

Congenital myasthenic syndromes; Fluoxetine; Quinidine; Slow channel; Treatment

Indexed keywords

3,4 DIAMINOPYRIDINE; FLUOXETINE; PREDNISOLONE; PYRIDOSTIGMINE; QUINIDINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL PROTOCOL; CONGENITAL MYASTHENIC SYNDROME; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; HUMAN; HYPOTENSION; MALE; MUSCLE FATIGUE; NERVE STIMULATION; OPTIMAL DRUG DOSE; PATIENT CARE; PHENOTYPE; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROTONERGIC CRISIS; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; CHOLINESTERASE INHIBITORS; FEMALE; FLUOXETINE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYASTHENIC SYNDROMES, CONGENITAL; PYRIDOSTIGMINE BROMIDE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862514328     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-011-6204-9     Document Type: Article

References (20)

1. Abicht A, Stucka R, Karcagi V, Herczegfalvi A, Horvath R, Mortier W, Schara U, Ramaekers V, Jost W, Brunner J, Janssen G, Seidel U, Schlotter B, Muller-Felber W, Pongratz D, Rudel R, Lochmuller H (1999) A common mutation (epsilon1267delG) in congenital myasthenic patients of Gypsy ethnic origin. Neurology 53:1564-1569 (Pubitemid 29491954)
2. Beeson D, Hantai D, Lochmuller H, Engel AG (2005) 126th International Workshop: congenital myasthenic syndromes, 24-26 September 2004, Naarden, the Netherlands. Neuromuscul Disord 15:498-512 (Pubitemid 40884475)
3. Colomer J, Muller JS, Vernet A, Nascimento A, Pons M, Gonzalez V, Abicht A, Lochmuller H (2006) Long-term improvement of slow-channel congenital myasthenic syndrome with fluoxetine. Neuromuscul Disord 16:329-333
4. Engel AG (2007) The therapy of congenital myasthenic syndromes. Neurotherapeutics 4:252-257 (Pubitemid 46467536)
5. Engel AG, Lambert EH, Mulder DM, Torres CF, Sahashi K, Bertorini TE, Whitaker JN (1982) A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 11:553-569 (Pubitemid 12116416)
6. Engel AG, Ohno K, Milone M, Wang HL, Nakano S, Bouzat C, Pruitt JN 2nd, Hutchinson DO, Brengman JM, Bren N, Sieb JP, Sine SM (1996) New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 5:1217-1227 (Pubitemid 26335838)
7. Engel AG, Sine SM (2005) Current understanding of congenital myasthenic syndromes. Curr Opin Pharmacol 5:308-321 (Pubitemid 40674255)
8. Fukudome T, Ohno K, Brengman JM, Engel AG (1998) Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor. Neuroreport 9:1907-1911 (Pubitemid 28289208)
9. Gomez CM, Maselli RA, Vohra BP, Navedo M, Stiles JR, Charnet P, Schott K, Rojas L, Keesey J, Verity A, Wollmann RW, Lasalde-Dominicci J (2002) Novel delta subunit mutation in slow-channel syndrome causes severe weakness by novel mechanisms. Ann Neurol 51:102-112 (Pubitemid 34027982)
10. Hantai D, Richard P, Koenig J, Eymard B (2004) Congenital myasthenic syndromes. Curr Opin Neurol 17:539-551 (Pubitemid 39410870)
11. Harper CM, Engel AG (1998) Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol 43:480-484 (Pubitemid 28231723)
12. Harper CM, Engel AG (1998) Safety and efficacy of quinidine sulfate in slow-channel congenital myasthenic syndrome. Ann NY Acad Sci 841:203-206 (Pubitemid 28362849)
13. Harper CM, Fukodome T, Engel AG (2003) Treatment of slowchannel congenital myasthenic syndrome with fluoxetine. Neurology 60:1710-1713 (Pubitemid 36618113)
14. Kinali M, Beeson D, Pitt MC, Jungbluth H, Simonds AK, Aloysius A, Cockerill H, Davis T, Palace J, Manzur AY, Jimenez-Mallebrera C, Sewry C, Muntoni F, Robb SA (2008) Congenital myasthenic syndromes in childhood: diagnostic and management challenges. J Neuroimmunol 201-202:6-12
15. Mihaylova V, Scola RH, Gervini B, Lorenzoni PJ, Kay CK, Werneck LC, Stucka R, Guergueltcheva V, von der Hagen M, Huebner A, Abicht A, Muller JS, Lochmuller H (2010) Molecular characterisation of congenital myasthenic syndromes in Southern Brazil. J Neurol Neurosurg Psychiatry 81:973-977
16. Muller JS, Mihaylova V, Abicht A, Lochmuller H (2007) Congenital myasthenic syndromes: spotlight on genetic defects of neuromuscular transmission. Expert Rev Mol Med 9:1-20 (Pubitemid 47261141)
17. Outteryck O, Richard P, Lacour A, Fournier E, Zephir H, Gaudon K, Eymard B, Hantai D, Vermersch P, Stojkovic T (2009) Novel epsilon subunit mutation of the muscle acetylcholine receptor causing a slow-channel congenital myasthenic syndrome. J Neurol Neurosurg Psychiatry 80:450-451
18. Schara U, Lochmuller H (2008) Therapeutic strategies in congenital myasthenic syndromes. Neurotherapeutics 5:542-547
19. Sine SM, Ohno K, Bouzat C, Auerbach A, Milone M, Pruitt JN, Engel AG (1995) Mutation of the acetylcholine receptor alpha subunit causes a slow-channel myasthenic syndrome by enhancing agonist binding affinity. Neuron 15:229-239
20. Whittington CJ, Kendall T, Pilling S (2005) Are the SSRIs and atypical antidepressants safe and effective for children and adolescents? Curr Opin Psychiatry 18:21-25 (Pubitemid 40332014)